• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 7, 2020

View Archived Issues
Cancer immunotherapy illustration

Atara deals mesothelin CAR T franchise to Bayer for up to $670M

Atara Biotherapeutics Inc. licensed a pair of mesothelin-directed CAR T treatments, ATA-2271 and ATA-3271, to Bayer AG for $60 million up front with the potential for $610 million in development, regulatory and commercialization milestone payments. Atara is also eligible for tiered royalties that peak in the low double-digit percentage of net sales of the two drugs. South San Francisco-based Atara will provide translational and clinical manufacturing services for the two drugs that will be reimbursed by Bayer. Read More

Biopharma shares on the move after ASH presentations

New data on a variety of blood disorder therapies announced at the 62nd American Society of Hematology (ASH) annual meeting moved company shares on Dec. 7. Shares of Fate Therapeutics Inc. (NASDAQ:FATE) hit a record high, rising 37.8% to $83.77 by day's end on news of clinical activity for one candidate in refractory diffuse large B-cell lymphoma. Read More
Coronavac shipment

Brazil’s Anvisa issues emergency pathway for COVID-19 vaccines, though some firms seek other routes

Brazilian health care regulator Anvisa has issued guidelines for SARS-CoV-2 vaccine manufacturers to receive emergency marketing approvals in the Latin American giant. Brazil is the largest market in the region and several COVID-19 vaccine makers are both doing trials there and hoping for quick approvals. Read More
US flag, Department of Health and Human Services flags

What does Biden’s HHS pick portend?

It’s official. After a weekend of rumors and speculation, President-elect Joe Biden formally announced the nomination of California Attorney General Xavier Becerra Dec. 7 as secretary of the U.S. Department of Health and Human Services, along with Vivek Murthy as surgeon general. Read More
Pills_generic.png

After years of effort, Japan slashes drug lag

TOKYO – Steadily over a decade and a half, Japan’s drugs and devices regulator has all but eliminated a huge drug lag that put the second largest drug market in the world well behind most others in terms of the time it took for approvals and patient access to innovative drugs. Read More

BIO, PhRMA challenge MFN model

The latest global regulatory news, changes and updates affecting biopharma, including: FDA, industry prepare for vaccine; FDA updates trial guidance; Labeling changes for diabetes drugs. Read More
Cancer-cell-antibody-attack

Bolting TLR agonist to antibody converts cold tumors

BioWorld looks at translational medicine. Read More
ICYMI illustration

ICYMI: Week in review, Nov. 30-Dec. 4, 2020

A quick look back at top stories. Read More

Appointments and advancements for Dec. 7, 2020

New hires and promotions in the biopharma industry, including: Achilles, Avadel, Bellus, Chimeron, GBT, Oncorus, Oyster Point, Rexgenero. Read More

Conference data for Dec. 7, 2020: ASH

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: Actinium, Allogene, Allovir, Amgen, Amphivena, Apellis, Arch Oncology, Astrazeneca, Attralus, Autolus, Beigene, Bergenbio, Biocryst, Bioniz, Bluebird, BMS, Cellectis, Constellation, Corvus, Crispr, Fate, Fulcrum, Gamida, GBT, Genentech, Gilead, Glycomimetics, IGM, Immunogen, IMV, Intellia, Janssen, Kite, Kura, Lilly, Macrogenics, Magenta, Orca Bio, Poseida, Regeneron, Rhizen, Rocket, Syndax, Syros, Vertex, Viracta. Read More

Financings for Dec. 7, 2020

Biopharmas raising money in public or private financings, including: 4D Molecular, Abcellera, Basking, Biocryst, Cogent, Enliven, Helix, Intellia, Nanobiotix, Repligen, Sinovac, Spirea, Trianni. Read More

In the clinic for Dec. 7, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 9 Meters, Alx, Arch Oncology, Arcturus, Arcutis, Brickell, Cel-Sci, Cytokinetics, Dare, Eisai, Genetx, Hookipa, Inovio, KPB, Lyra, Magenta, Neurorx, Odonate, Relief, Relmada, Sarepta, Tonix, Ultragenyx, Ysopia. Read More

Other news to note for Dec. 7, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3D Med, Accord Healthcare, Adelia, Aeterna, Aligos, Alloy, Astellas, Aurigene, Bioxcel, Boehringer, Bridgebio, Catalent, Consilient, Cybin, Exelixis, Eyam, Genscript, Gilead, Initium, Janssen, Kalivir, Marinus, Matinas, Maze, Menarini, Merck, Moderna, Nabriva, Orexo, Orsenix, Passage Bio, Pfizer, Postera, Proxygen, Qilu, Roivant, Sellas, Seqirus, Sesen Bio, Sherlock, Sinovant, Syneos, Syros, VBI, Xencor. Read More

Regulatory actions for Dec. 7, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allogene, Alzecure, Antengene, Artiva, Chimerix, Immunicum, Kronos, Lipocine, Neuren, Novo Nordisk, Scpharmaceuticals, Scynexis, Sol-Gel, Viracta, Yiling. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe